DSM Integrated Annual Report 2021

4 Segment information

In 2021, DSM’s reportable operating segments were Nutrition, Materials and the Innovation Center, as mentioned in Note 1 General Information. DSM has segmented its operations by business activity from which revenues are earned and expenses incurred. These operating results are regularly reviewed by the entity’s chief operating decision maker (CODM) to make decisions about resources to be allocated to the operating segment and assess its performance. DSM uses Adjusted EBITDA as the main indicator to evaluate the consolidated performance as well as the performance per operating segment. Discrete financial information is available for each identified operating segment.

The accounting policies of the operating segments are the same as those described in the Summary of significant accounting policies. Transactions between segments are generally executed at market-based prices. Interest income, interest expense, and income tax expense or income are not allocated to segments as these amounts are not included in the measure of segment profit or loss reviewed by the CODM, or otherwise regularly provided to the CODM.

Our operating segment Nutrition serves the global industries for animal feed, food & beverage, pharmaceuticals, infant nutrition, dietary supplements, and personal care. It does so by the production of pure active ingredients, their incorporation into sophisticated forms, and the provision of tailored premixes and forward solutions.

Our operating segment Materials is a global player in specialty plastics, which are used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries. Furthermore, Materials is a global player in providing innovative and sustainable ultra-strong, ultra-light Dyneema® fiber and fabrics.

Our operating segment Innovation Center focuses on innovation and the growth of DSM’s existing core business through adjacent technologies via its Corporate Research Program as well as through the company’s venturing and licensing activities. Additionally, it identifies and invests in new and innovative growth options. The Innovation Center is responsible for developing and extracting value from DSM’s Emerging Business Areas.

Any consolidated activities outside the three reportable operating segments above are reported as the reportable segment ‘Corporate Activities’. These mainly comprise operating and service activities as well as several costs that cannot be allocated to the operating segments.

DSM does not have a single external customer that represents 10% or more of total sales.

Geographical information

 

 

Nether­lands

 

Switzer­land

 

Rest of Europe

 

North America

 

Latin America

 

China

 

Rest of Asia

 

Rest of the world

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by origin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In € million

 

1,515

 

2,260

 

1,042

 

1,380

 

608

 

885

 

336

 

80

 

8,106

In %

 

19

 

28

 

13

 

17

 

7

 

11

 

4

 

1

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by destination

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In € million

 

407

 

214

 

2,125

 

1,791

 

1,045

 

991

 

1,268

 

265

 

8,106

In %

 

5

 

3

 

26

 

22

 

13

 

12

 

16

 

3

 

100

Workforce at year-end (headcount)1

 

3,858

 

2,129

 

4,384

 

3,185

 

2,243

 

5,025

 

1,996

 

307

 

23,127

Average workforce (FTE)1

 

3,708

 

2,135

 

3,625

 

3,195

 

2,108

 

4,950

 

1,803

 

291

 

21,815

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intangible assets and Property, plant and equipment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditure

 

110

 

159

 

114

 

76

 

15

 

93

 

4

 

2

 

573

Carrying amount

 

1,614

 

1,452

 

2,097

 

1,742

 

282

 

810

 

188

 

30

 

8,215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets (including assets held for sale)

 

4,084

 

2,125

 

2,676

 

2,552

 

776

 

1,382

 

639

 

112

 

14,346

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by origin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In € million

 

1,860

 

2,370

 

1,336

 

1,310

 

666

 

1,177

 

387

 

98

 

9,204

In %

 

20

 

26

 

15

 

14

 

7

 

13

 

4

 

1

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by destination

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In € million

 

374

 

163

 

2,644

 

1,916

 

1,198

 

1,187

 

1,438

 

284

 

9,204

In %

 

4

 

2

 

28

 

21

 

13

 

13

 

16

 

3

 

100

Workforce at year-end (headcount)

 

3,006

 

2,174

 

4,161

 

3,018

 

2,290

 

4,704

 

1,709

 

296

 

21,358

Average workforce (FTE)1

 

3,040

 

2,099

 

4,065

 

2,971

 

2,255

 

4,768

 

1,771

 

299

 

21,268

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intangible assets and Property, plant and equipment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditure

 

108

 

147

 

162

 

87

 

20

 

77

 

5

 

2

 

608

Carrying amount

 

1,990

 

1,733

 

2,073

 

2,201

 

291

 

836

 

113

 

30

 

9,267

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets (including assets held for sale)

 

4,566

 

2,593

 

2,738

 

3,116

 

864

 

1,459

 

576

 

101

 

16,013

1

Refers to total group, including discontinued operations.

Business segments

2021

 

Nutrition

 

Materials

 

Innovation Center

 

Corporate Activities

 

Elimi­nations

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial performance

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

7,031

 

1,935

 

168

 

70

 

-

 

9,204

Supplies to other clusters

 

46

 

12

 

18

 

 

 

(76)

 

-

Supplies

 

7,077

 

1,947

 

186

 

70

 

(76)

 

9,204

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA1

 

1,447

 

435

 

26

 

(94)

 

-

 

1,814

EBITDA

 

1,396

 

414

 

17

 

(125)

 

-

 

1,702

Adjusted operating profit1

 

940

 

331

 

4

 

(136)

 

-

 

1,139

Operating profit

 

889

 

310

 

(10)

 

(168)

 

-

 

1,021

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

484

 

100

 

23

 

39

 

-

 

646

Impairments

 

22

 

3

 

10

 

-

 

-

 

35

- of which included in APM adjustments

 

-

 

-

 

6

 

-

 

-

 

6

Additions to provisions

 

8

 

16

 

15

 

32

 

-

 

71

Result related to associates and joint ventures

 

(3)

 

-

 

1

 

344

 

-

 

342

R&D costs2

 

194

 

59

 

39

 

31

 

-

 

323

Employee benefit costs

 

1,233

 

253

 

65

 

259

 

-

 

1,810

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial position

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

11,002

 

1,570

 

566

 

2,819

 

563

 

16,013

Total liabilities

 

2,744

 

495

 

63

 

3,304

 

103

 

6,616

Capital employed at year-end

 

9,550

 

1,005

 

407

 

(1)

 

-

 

10,961

Capital expenditure

 

488

 

65

 

2

 

53

 

-

 

608

Share in equity of associates and joint ventures

 

38

 

3

 

1

 

22

 

-

 

64

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margin (in %)

 

20.6

 

22.5

 

-

 

-

 

-

 

19.7

 

 

 

 

 

 

 

 

 

 

 

 

 

Workforce

 

 

 

 

 

 

 

 

 

 

 

 

Average in fte

 

15,623

 

2,815

 

498

 

1,902

 

4303

 

21,268

Year-end (headcount)

 

16,091

 

2,885

 

578

 

1,804

 

 

 

21,358

1

See Note 2 Alternative performance measures for the reconciliation to Adjusted EBITDA of €1,814 million (2020: €1,534 million) and other IFRS performance measures.

2

R&D costs relate to the functional area Research & Development and exclude R&D costs included in the functional areas Cost of sales and Marketing & Sales as well as R&D expenditure capitalized.

3

The figures presented under ‘eliminations’ relate to the assets and liabilities reclassified as held for sale and the workforce for the discontinued operations.

Business segments

2020

 

Nutrition

 

Materials

 

Innovation Center

 

Corporate Activities

 

Elimi­nations

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial performance

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

6,365

 

1,518

 

184

 

39

 

-

 

8,106

Supplies to other clusters

 

53

 

8

 

21

 

 

 

(82)

 

-

Supplies

 

6,418

 

1,526

 

205

 

39

 

(82)

 

8,106

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA1

 

1,338

 

272

 

21

 

(97)

 

-

 

1,534

EBITDA

 

1,211

 

249

 

6

 

(98)

 

-

 

1,368

Adjusted operating profit1

 

919

 

168

 

(17)

 

(141)

 

-

 

929

Operating profit

 

792

 

145

 

(133)

 

(142)

 

-

 

662

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

407

 

99

 

38

 

43

 

-

 

587

Impairments

 

13

 

4

 

101

 

1

 

-

 

119

- of which included in APM adjustments

 

-

 

-

 

101

 

-

 

-

 

101

Additions to provisions

 

70

 

19

 

8

 

7

 

-

 

104

Results related to associates and joint ventures

 

(1)

 

-

 

(84)

 

53

 

-

 

(32)

R&D costs2

 

169

 

60

 

145

 

24

 

-

 

398

Employee benefit costs

 

1,102

 

226

 

83

 

273

 

-

 

1,684

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial position

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

9,477

 

1,035

 

599

 

2,139

 

1,0963

 

14,346

Total liabilities

 

2,451

 

379

 

37

 

3,738

 

2543

 

6,859

Capital employed at year-end

 

8,305

 

953

 

436

 

-

 

-

 

9,694

Capital expenditure

 

441

 

63

 

35

 

34

 

-

 

573

Share in equity of associates and joint ventures

 

30

 

3

 

2

 

58

 

-

 

93

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margin (in %)

 

21.0

 

17.9

 

 

 

 

 

 

 

18.9

 

 

 

 

 

 

 

 

 

 

 

 

 

Workforce

 

 

 

 

 

 

 

 

 

 

 

 

Average in fte

 

14,535

 

2,852

 

613

 

2,012

 

1,8033

 

21,815

Year-end (headcount)

 

15,838

 

2,857

 

579

 

2,039

 

1,8143

 

23,127

1

See Note 2 Alternative performance measures for the reconciliation to Adjusted EBITDA of €1,534 million and other IFRS performance measures.

2

R&D costs relate to the functional area Research & Development and exclude R&D costs included in the functional areas Cost of sales and Marketing & Sales as well as R&D expenditure capitalized.

2

The figures presented under ‘eliminations’ relate to the assets and liabilities reclassified as held for sale and the workforce for the discontinued operations.

Earnings before interest, tax, depreciation and amortization (EBITDA)
EBITDA is the sum of operating profit plus depreciation and amortization. Adjusted EBITDA is the EBITDA adjusted for material items of profit or loss coming from acquisitions/divestments, restructuring and other circumstances that management deem it necessary to adjust in order to provide clear reporting on the development of the business.